A phase 2 efficacy and safety study of SU011248 [sunitinib] administered in a continuous daily regimen in patients with advanced gastrointestinal stromal tumor
Latest Information Update: 25 Jun 2020
At a glance
- Drugs Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2020 Results (n=350) of simulation study from four clinical trials: study 1004, study 1047, study 1045 and study 013 assessing effects of dose increase on pharmacodynamic biomarkers can increase OS and retaining an acceptable safety profile published in the Clinical Cancer Research
- 01 Jul 2009 Results have been reported in the European Journal of Cancer.
- 01 Sep 2008 Results presented at the European Society for Medical Oncology.